Venus Metals rejects QGold's unsolicited takeover bid
Venus Metals urges shareholders to reject QGold's 17-cent takeover offer, citing undervaluation of assets including Youanmi royalty and Rox Resources stake. Takeover bid runs until January 16.
Venus Metals urges shareholders to reject QGold's 17-cent takeover offer, citing undervaluation of assets including Youanmi royalty and Rox Resources stake. Takeover bid runs until January 16.
Venus Metals urges shareholders to ignore QGold's 17-cent takeover offer, citing undervaluation of assets including Youanmi royalty and Rox Resources stake. Takeover bid runs until January 16.
BHP confirms it will not pursue a $100 billion takeover of Anglo American after preliminary discussions. Read the latest on this major mining sector development.
Treasurer Jim Chalmers blocks US firm's takeover of South Australian pharmaceutical company, citing national interest in healthcare security. Read the full details.
Treasurer Jim Chalmers addresses Japan's national security concerns about South Korea's Hanwha acquiring Australian shipbuilder Austal. Read the latest developments.
Dominique Roth battles rare CTX disease but the life-changing drug costs $500,000 annually. Her story highlights urgent need for PBS reforms to help Australians with rare conditions.
Japan formally voices security concerns to Australian Defence regarding South Korea's Hanwha bid for Austal. The move could impact regional defence partnerships.
Broadcasting legend Sandy Roberts celebrates as a $440,000 myeloma drug is added to the PBS, costing patients under $32. A game-changer for cancer treatment in Australia.
Japanese government expresses national security concerns as South Korea's Hanwha Group bids for Australian shipbuilder Austal. What this means for regional defence.
Alarming 400% increase in ADHD medication poisonings reported in Australia over past decade. Experts warn of growing prescription rates and accidental overdoses.
Australian pharmaceutical giant Mayne Pharma faces investor backlash as its controversial US licensing agreement continues to dominate trading, creating clear winners and losers on the ASX.
South Korea's defence powerhouse Hanwha Group remains in contention for a strategic investment in Australian shipbuilder Austal, potentially reshaping naval manufacturing in the region.